CBD (Cannabidiol)
CBD is a genuinely effective prescription anticonvulsant at 10-20 mg/kg/day — but the evidence for the reasons people actually buy it, anxiety, sleep and pain, is thin and inconsistent, and typical over-the-counter doses of 10-50 mg are far below anything ever shown to work. Product mislabelling is rampant.
What the science says
- Reduces seizures in Dravet and Lennox-Gastaut syndromes Strong evidence
In a randomised, double-blind trial of 120 children and young adults with Dravet syndrome, CBD 20 mg/kg/day cut median monthly convulsive seizures from 12.4 to 5.9, versus 14.9 to 14.1 on placebo. Replicated trials led to regulatory approval of pharmaceutical CBD (Epidiolex/Epidyolex) — this is a prescription medicine at doses roughly 20-100 times what consumer products contain.
- Reduces anxiety Limited evidence
A systematic review of randomised trials in anxiety found a small, heterogeneous literature dominated by single-dose experimental studies using 300-600 mg CBD in laboratory-induced anxiety, such as simulated public speaking. Trials of repeated dosing in diagnosed anxiety disorders are few and results are inconsistent, and no trial supports the 10-25 mg doses typical of retail gummies and oils.
- Improves sleep Limited evidence
Sleep is usually a secondary outcome in CBD trials, and reviews of non-seizure indications find no consistent benefit for insomnia. Where sleep improves, it often tracks improvement in the primary condition such as pain or anxiety rather than a direct hypnotic effect.
- Relieves chronic pain Limited evidence
Systematic reviews of randomised trials of CBD alone for chronic pain report little consistent separation from placebo. Much of the positive cannabis pain literature involves THC-containing preparations, which is a different question entirely.
Dosage & safety
Scientific references
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
- The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
- Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022)
Where to buy
View on iHerbReferral link — this site may earn a commission on purchases.
Related in Stress & mood
- Ashwagandha Moderate evidence
- L-Methylfolate Limited evidence
- 5-HTP Limited evidence
- L-Ornithine Limited evidence
- SAM-e Moderate evidence
- Rhodiola Rosea Limited evidence